Biotech Daily Market Report December 12, 2006
December 12th 2006 07:03
ASX, BIOTECHS EVEN:
BIONOMICS UP 16%, PHYLOGICA DOWN 7%
BIONOMICS UP 16%, PHYLOGICA DOWN 7%
THE MARKET
The Australian stock market closed virtually unchanged on Tuesday December 12, 2006, with the All Ordinaries up 0.6 points to 5,456.1 points. Seventeen of the Biotech Daily Top 40 stocks were up, 15 stocks fell, seven traded unchanged and one was untraded. Eleven of the Top 20 rose and seven fell, while six of the Second 20 rose and eight fell.
Bionomics was best on no news up three cents or 15.79 percent to 22 cents with 70,000 shares traded followed by Progen which last traded up 27 cents or 6.96 percent to $4.15 on moderate volumes before calling a trading halt (see separate story).
Alchemia and Biota were both up more than four percent; Agenix and Prima climbed more than three percent; Cellestis, Novogen and Peplin were up more than two percent; with Evogenix, Genetic Technologies, Metabolic and Neuren up more than one percent.
Phylogica led the falls down 2.5 cents or 7.04 percent to 33 cents with 71,000 shares traded but Peptech saw 2.3 million shares change hands as it retreated from yesterday’s stellar rise, down 10 cents or 6.06 percent to $1.55, with Clinical Cell shedding 0.6 cents or 6.0 percent to 9.4 cents with 4.4 million shares traded.
Phosphagenics fell 4.29 percent; Chemgenex and Proteome fell more than three percent; Biosignal, Cogstate and Living Cell fell more than two percent; with Avexa, Clinuvel, Cochlear, Cygenics, Cytopia, Optiscan and Prana down more than one percent.
TODAY’S NEWS
* PRIMA CLOSES PHASE IIa OVARIAN CANCER TRIAL
* CYTOPIA BEGINS PHASE I ORAL ROUTE TUMOR TRIAL
* PHOSPHAGENICS TO RAISE $15m IN PLACEMENT, PLAN
* PROGEN IN RESULTS TRADING HALT
* IDT PLEADS SCHULTZ TO ASX QUERY
* GARRY KAAN REPLACES APOLLO CFO ROY BROWN
To view these articles readers need to subscribe to Biotech Daily.
See details at www.biotechdaily.com.au
| 24 |
| Vote |
Add To: 
subscribe to this blog